Momil (Mometasone Furoate)

Mometasone furoate is an agonist of the glucocorticoid receptor. After binding to the receptor inside nasal mucosal cells, it alters gene transcription, suppressing the production of inflammatory cytokines, chemokines and adhesion molecules. This reduces swelling, mucus production and the infiltration of inflammatory cells, providing anti‑inflammatory and immunosuppressive effects locally.

The specific dosing regimen for Momil is determined by the prescribing clinician based on the patient’s age, severity of symptoms and overall treatment plan. Healthcare providers will instruct the number of sprays per nostril and the frequency of administration, and patients should follow that guidance precisely.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. The product should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their obstetrician or healthcare provider.

To request Momil, visit the product page on gnhindia.com, enter the required quantity and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Momil (mometasone furoate) is a high‑potency intranasal corticosteroid with a low systemic bioavailability, similar to other agents such as fluticasone propionate or budesonide. Clinical studies suggest comparable efficacy in controlling allergic rhinitis symptoms, while its once‑daily dosing and favorable safety profile make it a convenient option for many patients.

Momil should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the spray tip remains clean. Do not freeze the nasal spray.

Momil is administered as a nasal spray. The patient gently tilts the head forward, inserts the nozzle into one nostril, and sprays the prescribed number of sprays while breathing in gently through the nose. The same procedure is repeated in the other nostril if directed by the prescriber.

Serious risks, although rare, include nasal septal perforation, cataracts or increased intra‑ocular pressure, suppression of the hypothalamic‑pituitary‑adrenal axis, and opportunistic fungal infections of the nasal mucosa. Patients should report persistent nosebleeds, visual changes, severe headache or signs of systemic steroid exposure to their healthcare provider promptly.

Momil is contraindicated in individuals with known hypersensitivity to mometasone furoate or any component of the formulation. It should also be avoided in patients with recent nasal surgery, severe nasal trauma, or active untreated nasal infections unless directed by a physician.